TuHURA Biosciences Received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB To Stage IV Cutaneous Melanoma (TuHURA Biosciences)
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, announced that the U.S FDA has granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.
Skin Cancer Vaccine Developed by Tampa Company Enters Phase 1 of Clinical Trial
UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc. completed its first-in-human phase one trial in cutaneous melanoma at Moffitt Cancer Center within the past year and has now moved into studying patients in earlier stages of skin cancers.
Signet Medical Solutions, Inc. Announces Option to Acquire Rights of Method to Detect Melanoma Cancer by Smell
Tom Donaldson, President, announced that Signet executed an Option to license all rights to medical non-invasive system to detect melanoma skin cancer using a vapor analysis system. The technology was developed by a University of Florida team led by Dr. Nikolaus Gravenstein, professor of anesthesiology, as well as a professor of neurosurgery and professor of […]